VIVJOA (oteseconazole)

About Mycovia Pharmaceuticals

Mycovia Pharmaceuticals is a private, commercial-stage biotech founded in 2018, headquartered in the Research Triangle Park. The company has successfully brought its first product, VIVJOA, to market for recurrent vulvovaginal candidiasis (RVVC), representing a significant advancement in a chronic, underserved women's health condition. With a leadership team rich in pharmaceutical development and antifungal expertise, Mycovia is positioned to capitalize on this approved therapy while potentially expanding its pipeline into other antifungal indications. The company operates with a therapeutics business model and is now in a revenue-generating stage.

Therapeutic Areas